Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
Cancer Therapies02:49

Cancer Therapies

7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survivin, the promising target in hepatocellular carcinoma gene therapy.

Cancer biology & therapy·2008
Same author

Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture.

Neurochemical research·2008
Same author

Cellular mechanisms of reduced sarcoplasmic reticulum Ca2+ content in L-thyroxin induced rat ventricular hypertrophy.

Acta pharmacologica Sinica·2008
Same author

Promoting the formation and stabilization of G-quadruplex by dinuclear RuII complex Ru2(obip)L4.

Inorganic chemistry·2008
Same author

Identification of direct target genes using joint sequence and expression likelihood with application to DAF-16.

PloS one·2008
Same author

In vitro and in vivo investigations on the antiviral activity of a series of mixed-valence rare earth borotungstate heteropoly blues.

European journal of medicinal chemistry·2008

Related Experiment Video

Updated: May 28, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

10.9K

Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving

Zhi-Yuan Yao1, Xiao Ma1,2, Yong-Zheng Cui3

  • 1Department of Oncology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221000, Jiangsu Province, China.

World Journal of Gastroenterology
|February 10, 2025
PubMed
Summary
This summary is machine-generated.

The triglyceride glucose (TyG) index, a marker for insulin resistance, predicts better outcomes for advanced gastric cancer patients receiving immunotherapy and chemotherapy. A high TyG index indicates a favorable prognosis and improved treatment efficacy.

Keywords:
EfficacyGastric cancerPrognostic modelSafetySintilimabTriglyceride glucose index

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.1K

Related Experiment Videos

Last Updated: May 28, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

10.9K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

17.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.1K

Area of Science:

  • Oncology
  • Metabolic Syndrome
  • Immunotherapy

Background:

  • Gastric cancer (GC) is a leading cause of cancer death globally, with poor prognosis despite immunotherapy advancements.
  • Insulin resistance, indicated by the triglyceride glucose (TyG) index, influences cancer progression and immune responses.
  • The prognostic role of the TyG index in advanced GC requires further investigation.

Purpose of the Study:

  • To evaluate the TyG index as a predictive marker for advanced gastric cancer (GC) patients undergoing chemo-immunotherapy.
  • To determine if the TyG index can forecast treatment efficacy and patient survival.

Main Methods:

  • Retrospective analysis of 300 advanced GC patients treated with sintilimab and chemotherapy.
  • Patients were stratified into high and low TyG index groups.
  • Cox regression analysis identified independent prognostic factors, leading to a nomogram model.

Main Results:

  • High TyG index group showed significantly longer progression-free survival and overall survival (OS).
  • Objective response and disease control rates were higher in the high TyG index group.
  • TyG index, ECOG score, and PD-L1 expression were independent prognostic factors for OS.

Conclusions:

  • The TyG index is a valuable long-term predictor of chemo-immunotherapy efficacy in advanced GC.
  • Patients with a high TyG index demonstrate a better prognosis and treatment response.
  • The TyG index, alongside ECOG and PD-L1, aids in predicting patient outcomes.